Additional Gram-Negative Discovery and Development Programs


Achaogen is drawing on knowledge gained through its work on LpxC inhibitors to identify compounds that bind and inhibit additional essential enzymes in the gram-negative outer membrane biosynthesis pathway. These targets are attractive for many of the same reasons as LpxC: their inhibition leads to rapid cell death, they are highly conserved among the gram-negative bacteria, and they have no similar mammalian genes, reducing the potential for mechanism-based toxicity in patients. We are seeking to identify these compounds by using structure-guided design and virtual fragment screening based on the crystal structures of these enzymes.

Learn more about how we discover and develop gram-negative product candidates by relying on novel techniques, deep knowledge and expert capabilities.